{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:31:27Z","timestamp":1775910687813,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16388"],"award-info":[{"award-number":["21K16388"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10549-023-07115-7","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:04:06Z","timestamp":1695222246000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer"],"prefix":"10.1007","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-3067","authenticated-orcid":false,"given":"Yumiko","family":"Ishizuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Onagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"7115_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1634\/theoncologist.12-7-884","volume":"12","author":"AF Eichler","year":"2007","unstructured":"Eichler AF, Loeffler JS (2007) Multidisciplinary management of brain metastases. Oncologist 12:884\u2013898","journal-title":"Oncologist"},{"key":"7115_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-014-3090-8","volume":"147","author":"N Niikura","year":"2014","unstructured":"Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K et al (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103\u2013112","journal-title":"Breast Cancer Res Treat"},{"key":"7115_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M et al (2019) Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121:991\u20131000","journal-title":"Br J Cancer"},{"key":"7115_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-017-4107-x","volume":"162","author":"S Matsuo","year":"2017","unstructured":"Matsuo S, Watanabe J, Mitsuya K, Hayashi N, Nakasu Y, Hayashi M (2017) Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res Treat 162:169\u2013179","journal-title":"Breast Cancer Res Treat"},{"key":"7115_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-021-06246-z","volume":"189","author":"J Watanabe","year":"2021","unstructured":"Watanabe J, Mitsuya K, Nakamoto S, Harada H, Deguchi S, Hayashi N et al (2021) Leptomeningeal metastasis in ER + HER2- advanced breast cancer patients: a review of the cases in a single institute over a 15-year period. Breast Cancer Res Treat 189:225\u2013236","journal-title":"Breast Cancer Res Treat"},{"key":"7115_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","volume":"124","author":"C Bailleux","year":"2021","unstructured":"Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124:142\u2013155","journal-title":"Br J Cancer"},{"key":"7115_CR7","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/cancers13051078","volume":"13","author":"C Watase","year":"2021","unstructured":"Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y et al (2021) Breast cancer brain metastasis-overview of disease state, treatment options and future perspectives. Cancers (Basel) 13:1078","journal-title":"Cancers (Basel)"},{"key":"7115_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u201cBRCAness\u201d in sporadic cancers. Nat Rev Cancer 4:814\u2013819","journal-title":"Nat Rev Cancer"},{"key":"7115_CR9","doi-asserted-by":"publisher","first-page":"21173","DOI":"10.1038\/s41598-020-78016-8","volume":"10","author":"L Liu","year":"2020","unstructured":"Liu L, Matsunaga Y, Tsurutani J, Akashi-Tanaka S, Masuda H, Ide Y et al (2020) BRCAness as a prognostic indicator in patients with early breast cancer. Sci Rep 10:21173","journal-title":"Sci Rep"},{"key":"7115_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12282-021-01319-9","volume":"29","author":"A Sueta","year":"2022","unstructured":"Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H et al (2022) Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer 29:368\u2013376","journal-title":"Breast Cancer"},{"key":"7115_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167016","volume":"11","author":"H Mori","year":"2016","unstructured":"Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y et al (2016) BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer. PLoS One 11:e0167016","journal-title":"PLoS One"},{"key":"7115_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165721","volume":"11","author":"H Tanino","year":"2016","unstructured":"Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M et al (2016) BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. PLoS One 11:e0165721","journal-title":"PLoS One"},{"key":"7115_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jss.2019.12.047","volume":"250","author":"S Teraoka","year":"2020","unstructured":"Teraoka S, Sato E, Narui K, Yamada A, Fujita T, Yamada K et al (2020) Neoadjuvant chemotherapy with anthracycline-based regimen for BRCAness tumors in triple-negative breast cancer. J Surg Res 250:143\u2013147","journal-title":"J Surg Res"},{"key":"7115_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New Engl J Med 377:523\u2013533","journal-title":"New Engl J Med"},{"key":"7115_CR15","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. New Engl J Med 384:2394\u20132405","journal-title":"New Engl J Med"},{"key":"7115_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13058-017-0861-2","volume":"19","author":"TM Severson","year":"2017","unstructured":"Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC et al (2017) The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res 19:99","journal-title":"Breast Cancer Res"},{"key":"7115_CR17","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3390\/cancers14112640","volume":"14","author":"R Abbotts","year":"2022","unstructured":"Abbotts R, Dellomo AJ, Rassool FV (2022) Pharmacologic induction of BRCAness in BRCA-proficient cancers: Expanding PARP inhibitor use. Cancers (Basel) 14:2640","journal-title":"Cancers (Basel)"},{"key":"7115_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-022-00427-8","volume":"10","author":"M Oshi","year":"2022","unstructured":"Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A et al (2022) Development of a novel BRCAness score that predicts response to PARP inhibitors. Biomark Res 10:80","journal-title":"Biomark Res"},{"key":"7115_CR19","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/cancers13051004","volume":"13","author":"MM Ladan","year":"2021","unstructured":"Ladan MM, van Gent DC, Jager A (2021) Homologous recombination deficiency testing for BRCA-like tumors: the road to clinical validation. Cancers (Basel) 13:1004","journal-title":"Cancers (Basel)"},{"key":"7115_CR20","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdy216","volume":"29","author":"M Diossy","year":"2018","unstructured":"Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C et al (2018) Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol 29:1948\u20131954","journal-title":"Ann Oncol"},{"key":"7115_CR21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","volume":"22","author":"MA Vollebergh","year":"2011","unstructured":"Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH et al (2011) An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22:1561\u20131570","journal-title":"Ann Oncol"},{"key":"7115_CR22","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1186\/bcr3049","volume":"13","author":"EH Lips","year":"2011","unstructured":"Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AMM, Imholz ALT et al (2011) Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 13:R107","journal-title":"Breast Cancer Res"},{"key":"7115_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-008-0117-z","volume":"116","author":"SA Joosse","year":"2009","unstructured":"Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N et al (2009) Prediction of BRCA1-association in hereditary non-BRCA1\/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 116:479\u2013489","journal-title":"Breast Cancer Res Treat"},{"key":"7115_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16:110\u2013120","journal-title":"Nat Rev Cancer"},{"key":"7115_CR25","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"P Polak","year":"2017","unstructured":"Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G et al (2017) A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet 49:1476\u20131486","journal-title":"Nat Genet"},{"key":"7115_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-017-0856-z","volume":"19","author":"S Vos","year":"2017","unstructured":"Vos S, Moelans CB, van Diest PJ (2017) BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Res 19:64","journal-title":"Breast Cancer Res"},{"key":"7115_CR27","doi-asserted-by":"publisher","first-page":"37080","DOI":"10.18632\/oncotarget.26354","volume":"9","author":"K Sun","year":"2018","unstructured":"Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G et al (2018) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9:37080\u201337096","journal-title":"Oncotarget"},{"key":"7115_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.gore.2016.10.004","volume":"18","author":"M Bangham","year":"2016","unstructured":"Bangham M, Goldstein R, Walton H, Ledermann JA (2016) Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease. Gynecol Oncol Rep 18:22\u201324","journal-title":"Gynecol Oncol Rep"},{"key":"7115_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jog.13851","volume":"45","author":"I Sakamoto","year":"2019","unstructured":"Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M (2019) Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: a case report. J Obstet Gynaecol Res 45:743\u2013747","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"7115_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ijc.34525","volume":"153","author":"E Senkus","year":"2023","unstructured":"Senkus E, Delaloge S, Domchek SM, Conte P, Im SA, Xu B et al (2023) Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer 153(4):803\u2013814","journal-title":"Int J Cancer"},{"key":"7115_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.36401\/JIPO-20-24","volume":"4","author":"TC Lam","year":"2021","unstructured":"Lam TC (2021) Comprehensive genomic profiling-guided niraparib treatment of triple-negative breast cancer in a patient with extensive brain metastasis: case report and literature review. J Immunother Precis Oncol 4:16\u201320","journal-title":"J Immunother Precis Oncol"},{"key":"7115_CR32","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418\u20138423","journal-title":"Proc Natl Acad Sci USA"},{"key":"7115_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.humpath.2007.10.011","volume":"39","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39:857\u2013865","journal-title":"Hum Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07115-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T07:46:59Z","timestamp":1704700019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07115-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["7115"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07115-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Juntendo University Hospital (H16-0096-H01) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"An opt-out approach was used with the disclosure of website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}